Disease · MONDO_0000873
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SC-PEG (Arm A) vs Oncaspar (Arm B): deaths from any cause | 7 of 119 | 5 of 120 | 239 | NCT01574274 | Trial comparisons |
| SC-PEG (Arm A) vs Oncaspar (Arm B): serious adverse events | 35 of 119 | 27 of 120 | 239 | NCT01574274 | Trial comparisons |
| SC-PEG (Arm A) vs Oncaspar (Arm B): Number of Participants With Asparaginase-Related Toxicity | 41 of 109 | 43 of 114 | 223 | NCT01574274 | Trial comparisons |
| All-2 vs L-20: serious adverse events | 39 of 81 | 33 of 89 | 170 | NCT00002766 | Trial comparisons |
| Ph+ Subjects vs Ph- Subjects: Number of Participants With Morphological Complete Response Rate | 27 of 28 | 20 of 25 | 53 | NCT03023046 | Trial comparisons |
| Conventional Care vs Intensive Insulin: serious adverse events | 9 of 25 | 10 of 26 | 51 | NCT00500240 | Trial comparisons |
| Hyper-CMAD + Rituximab vs Hyper-CMAD: Number of Patients With Complete Remission at One Year | 12 of 15 | 13 of 16 | 31 | NCT01319981 | Trial comparisons |
| Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Number of Participants With at Least Partial Response to Palbociclib | 4 of 6 | 1 of 6 | 12 | NCT03792256 | Trial comparisons |
| Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Frequency of Dose Limiting Toxicities of Palbociclib | 1 of 6 | 0 of 6 | 12 | NCT03792256 | Trial comparisons |
| Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Frequency of Adverse Events of Palbociclib | 5 of 6 | 5 of 6 | 12 | NCT03792256 | Trial comparisons |
| Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: deaths from any cause | 2 of 6 | 1 of 6 | 12 | NCT03792256 | Trial comparisons |
| Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: serious adverse events | 6 of 6 | 6 of 6 | 12 | NCT03792256 | Trial comparisons |
| Ixazomib Dose Level 1 (Stratum A) vs Ixazomib Dose Level 2 (Stratum A): Phase 1: Dose Limiting Toxicity (DLT) During Block 1 of Chemotherapy | 0 of 3 | 0 of 6 | 9 | NCT03817320 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000873/comparisons